Celprogen, Inc

ProteoGenex is an established, innovative provider of biological specimens and clinical information of the highest quality standards.

We are a privately held US company founded in Los Angeles, CA in 2003. With headquarters in Culver City, CA, we also have a large, state-of-the-art research laboratory in Moscow, Russia.

The ProteoGenex team consists of 35 employees, including 30 Molecular Biologists, Cell Biologists, Biochemists, and Pathologists (15 PhDs, 5 MDs, 15 MSs).

Our biorepository offers an extensive inventory of biospecimens as well as an exclusive, custom-design human tissue-based research service, which is the company’s largest and fastest growing business segment.
Our unique and comprehensive biobank is composed of well-defined and categorized clinical samples, including frozen and FFPE tissues, blood, serum, plasma, bone marrow, tissue microarrays, etc. All ProteoGenex specimens are collected from a vast network of academic and professional clinical institutions under strict regulatory and ethical standards.

We have over 200,000 individual biomaterials covering disease targets in the fields of Oncology, Dermatology, Neurology, Immunology, Infectious Diseases, Autoimmune and Metabolic Disorders, and many more. Our products are derived from a variety of diseased human sources as well as from normal tissues. All specimens are supported by extensive pathology information and patient’s’ clinical history documentation.

Drug Discovery Alliances is a provider of chemistry and formulation services bringing together scientific expertise and support during all stages of the R&D continuum for emerging biotechs, existing multinationals and the United States government. We provide a global service where our partners – located in N. America, China, Japan, Czech Republic, England, Germany and Italy – cover four key services:

Consulting
• CMC Project Management
• GMP Auditing
• Licensing
• Sourcing & Procurement

Drug Discovery
• Medicinal Chemistry

R&D/Pre-Clinical
• Analytical Method Development
• Catalysis Screening
• Crystallization
• Metabolites, Impurities ID & Synthesis
• Process Research
• Reference Standards
• Solid Form Capabilities

Manufacturing (Phase I-III)
• Advanced Intermediate Manufacturing
• API & Commercial Manufacturing
• cGMP Manufacturing
• Final Drug Product Manufacturing
• Formulation Development
• Quality and Regulatory Support
• Raw Material Manufacturing

Chemistry Technology Platforms
Aseptic Fill & Finish
• Chlorination
• Chromatography
• Cryogenic
• Distillation
• Fermentation
• Heck Reactions
• HPAPI / High Potency
• High Pressure
• High Temperature
• High Throughput / High Resolution X-ray Diffraction
• Hydrogenation
• Lyophilization
• Nitration
• Pastillation
• Phosgenation
• Polymorph Screening
• Powder Filling
• X-ray Crystallography

Project Examples
• 4 year program for development of Regulatory Starting Material supporting NDA filing for a neurology product
• Urgent API consulting for Clinical Phase III with supplier change and identified savings of $10M
• CMC project consulting on pre-IND candidates ($760M) for a CNS product licensed by Astellas
• Generic new formulation consulting supporting Clinical Phase III for 505(b)(2) for hypertension product
• Commercial API manufacture for ophthalmology product sourcing key suppliers leading to successful FDA approval
• Phase III API for antibody conjugate for oncology identifying key supplier

A biotechnology company which provides quality life science products, such as, antibodies, reagents, and assays for inflammatory and autoimmune diseases, pain, metabolism, oncology, and neurology research.

Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.

Tissue Diagnostics (TDx) offers comprehensive tissue based assay development and validation services based on Immunohistochemistry (IHC) and In-situ Hybridization (ISH) methodologies to support early and late stage Oncology, Neurology and Immunology research studies. Our team has extensive industry experience in Biomarker testing, Companion Diagnostics Development and validation utilizing cutting edge methods and knowledge. We integrate our experience in tissue based assay development, histopathology services and specimen management services to provide high quality, consistent and reliable results to Biotechnology companies and Universities nationwide.


TDx is dedicated to providing laboratory testing services to support the Biotechnology and Pharmaceutical companies and Clinical Research Organizations (CRO) looking for laboratory facilities with dedicated infrastructure and personnel.

In addition to our research focus, we offer routine Histopathological and IHC staining services to Hospitals, Surgery Centers and Independent Labs.